One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
Dr. Llovet (Clínic-IDIBAPS) and Dr. Bustelo (CSIC-University of Salamanca) coordinate the ASPIRE-AECC project, which includes 15 hospitals to conduct1
Researchers from the Hospital Clínic-IDIBAPS have published a review in Nature Reviews Clinical Oncology about the adjuvant and neoadjuvant treatment1
Endowed with €12 million, the project is coordinated by Prof. Josep M. Llovet, the head of the IDIBAPS group Translational Research in Hepatic Oncolo1
Clarivate Analytics has published its ranking of the most cited researchers in the world, the Highly Cited Researchers, which identifies the most inf1
The aim of the new programme is to increase the survival of cancer patients by improving the detection of populations at risk and early diagnosis, as1
The candidature of the Clínic-IDIBAPS researcher was approved with 90% of the votes at the general assembly of the European Association for the Study1
They are the Translational cancer research program, the Synaptic autoimmunity in neurology, psychiatry and cognitive neuroscience program and the Lym1
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
On Monday, March 13, the Spanish Association Against Cancer (AECC) announced the 2022 AECC Cancer Research Grants.
